Impact of genetic markers on treatment of non-small cell lung cancer

Nicholas Lamparella, Amit Barochia, Salah Almokadem

Research output: Chapter in Book/Report/Conference proceedingChapter

9 Scopus citations


Non-small cell lung cancer represents a group of heterogeneous diseases. The last decade witnessed significant progress in improving our understanding of the biology of non-small cell lung cancer, which led to the identification of several genetic targets. Those genetic targets were utilized to explain clinical phenomena, such as the occurrence of non-small cell lung cancer in never-smokers, to predict response to conventional chemotherapy and biological agents, and to explain and predict resistance to therapy. The progress in the treatment of non-small cell lung cancer in the last few years was based on a new generation of population-enriched clinical trials that utilized genetic targets such as somatic EGFR mutations and ALK-EML4 mutations. In this review we will discuss the available information about the key genetic markers of non-small cell lung cancer and the pivotal clinical trials that validate the use of those genetic markers in non-small cell lung cancer patients.

Original languageEnglish (US)
Title of host publicationImpact of Genetic Targets on Cancer Therapy
PublisherSpringer Science and Business Media, LLC
Number of pages20
ISBN (Print)9781461461753
StatePublished - 2013

Publication series

NameAdvances in Experimental Medicine and Biology
ISSN (Print)0065-2598

All Science Journal Classification (ASJC) codes

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Impact of genetic markers on treatment of non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this